FDA Questions Evidence For Janssen’s Xarelto In Acute Coronary Syndrome
This article was originally published in The Pink Sheet Daily
Executive Summary
Although FDA suggested the sponsor consider a limited duration of use for rivaroxaban in the ACS setting, advisory committee briefing documents reflect doubts about the strength of analyses supporting such a claim.